Cassava Sciences, Inc. (SAVA): Price and Financial Metrics


Cassava Sciences, Inc. (SAVA)

Today's Latest Price: $15.68 USD

2.81 (21.83%)

Updated Jan 25 6:55pm

Add SAVA to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

SAVA Stock Price Chart Interactive Chart >

Price chart for SAVA

SAVA Price/Volume Stats

Current price $15.68 52-week high $15.80
Prev. close $12.87 52-week low $1.63
Day low $13.22 Volume 4,256,600
Day high $15.80 Avg. volume 3,964,333
50-day MA $8.57 Dividend yield N/A
200-day MA $6.36 Market Cap 401.08M

Cassava Sciences, Inc. (SAVA) Company Bio

Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.

Most Popular Stories View All

• Is General Motors the Next Tesla?

• How to Outperform the Stock Market in 2021

• 2 Chinese Stocks Rated Strong Buy: EHang and Daqo

• 3 Lesser-Known Cloud Stocks to Add to Your Portfolio

• Is Virgin Galactic a Buy After a New Space Stock ETF was announced?

View All Top Stories

SAVA Latest News Stream

Event/Time News Detail
Loading, please wait...
View All SAVA News

SAVA Latest Social Stream

Loading social stream, please wait...

View Full SAVA Social Stream

Latest SAVA News From Around the Web

Below are the latest news stories about Cassava Sciences Inc that investors may wish to consider to help them evaluate SAVA as an investment opportunity.

The 3 Best Healthcare Stocks to Buy for 2021

These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.

Yahoo | January 23, 2021

Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company’s Phase 3 development of simufilam for Alzheimer’s disease.AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the executive management team, reporting to the President & CEO.“We are delighted to have Dr. Kupiec join our team,” said ...

Yahoo | January 4, 2021

Is SAVA A Good Stock To Buy Now?

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

Yahoo | December 8, 2020

USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’

Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be SimufilamAUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simufilam.’ This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO’s advice. Future references to Cassava Sciences’ lead drug candidate for Alzheimer’s disease will be simufilam.About USAN The United States Adopted Names Council is responsible for selecting simple, informative and unique nonproprietary drug names. The USAN Council establishes logical nomenclature cla...

Yahoo | November 27, 2020

Zoetis (ZTS) Librela Gets Marketing Authorization in Europe

Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.

Yahoo | November 13, 2020

Read More 'SAVA' Stories Here

SAVA Price Returns

1-mo N/A
3-mo 80.85%
6-mo 393.08%
1-year 119.30%
3-year 115.09%
5-year 39.13%
YTD 129.91%
2020 31.15%
2019 511.76%
2018 -78.75%
2017 0.25%
2016 -67.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.742 seconds.